Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults.
about
Pneumococcal vaccination of older adults: conjugate or polysaccharide?Pneumococcal Vaccination in High-Risk Individuals: Are We Doing It Right?A case series evaluating the serological response of adult asthma patients to the 23-valent pneumococcal polysaccharide vaccine.The ABC of pneumococcal infections and vaccination in patients with chronic kidney disease.Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cellsRandomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults.Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review.Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adultsLong-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease.Long-term immune responses and comparative effectiveness of one or two doses of 7-valent pneumococcal conjugate vaccine (PCV7) in HIV-positive adults in the era of combination antiretroviral therapy.No long-term evidence of hyporesponsiveness after use of pneumococcal conjugate vaccine in children previously immunized with pneumococcal polysaccharide vaccineSafety and immunogenicity of a single dose 23-valent pneumococcal polysaccharide vaccine in Russian subjects.Pneumococcal polysaccharide vaccination induces polysaccharide-specific B cells in adult peripheral blood expressing CD19⁺CD20⁺CD3⁻CD70⁻CD27⁺IgM⁺CD43⁺CD5⁺/⁻Theory and strategy for Pneumococcal vaccines in the elderly.Pneumococcal vaccination among adults with chronic respiratory diseases: a historical overview.Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice.Vaccine responsiveness in the elderly: best practice for the clinic.Discrepant serological assays for Pneumococcus in renal transplant recipients - a prospective study.Neoglycoconjugate of Tetrasaccharide Representing One Repeating Unit of the Streptococcus pneumoniae Type 14 Capsular Polysaccharide Induces the Production of Opsonizing IgG1 Antibodies and Possesses the Highest Protective Activity As Compared to HeLong-term persistence of the immune response to antipneumococcal vaccines after Allo-SCT: 10-year follow-up of the EBMT-IDWP01 trial.Pneumococcal conjugate vaccination for older adults: Reply letter to Hollingsworth et al.Vaccination choices for older people, looking beyond age specific approaches.Background paper to the updated pneumococcal vaccination recommendation for older adults in Germany.Active surveillance of 2017 seasonal influenza vaccine safety: an observational cohort study of individuals aged 6 months and older in Australia
P2860
Q27690289-0DB6AD08-C530-4680-8705-0DA6F812F5DEQ28070059-7F3FF69E-DFA6-432C-9889-6D46B422D1D7Q33776577-C7653796-5DBE-476B-A693-D286EB3244D9Q35633471-C71A2071-4A88-4F6A-93B9-4A17B72FCFAFQ35883435-155ACC2A-1DD3-4005-B71B-294C0E848725Q36154661-E6C59149-524C-4F49-8F1A-A709A72E360BQ36204195-7C8B4F51-7FC8-4966-9B13-E4F9DA662726Q36255837-A4D0171A-FDD5-4A40-90C4-F87D6A48DC63Q36379580-3437D189-1479-4CE9-B767-D96103AF4039Q36523805-AC61DB70-0072-4A6A-8439-71D9C1CC2C81Q36984795-86BFD39A-88F0-4D5C-AB99-3E04CB6383FEQ37197130-C77A549C-235D-49CA-94FD-EA44AE65C136Q37260884-7F45F59A-3A4E-462E-83F5-31EFD156D33FQ37309215-08766733-DF64-4791-ABAE-8D4E042A598DQ37981768-1BBF8AE2-5B79-49FF-BDC2-D3612E6E0A26Q38082673-29E3B1AD-6D83-4B16-8EEF-0157FAF195B5Q38217108-69DF4F83-5D19-49DB-AAE8-15BF88DFBF34Q38739122-A18A482C-C6C2-4E49-A0CB-7BDAAD8C8D31Q40167840-954DED5A-1CD9-4CAE-96C7-7D44593D4C87Q41081873-54FA37C5-956D-4C1C-A057-E52542BFA1E6Q42923024-7318B188-E4B0-4CAE-8F1E-AE0ACD816EFAQ47595817-96E3901E-7AFE-4D23-BA4A-D05D60B83EDAQ52844673-4C3A04E3-3819-416A-B0FA-03AD486626B9Q57812045-EFBE0D33-1964-4AA4-9B89-12178AF36A13
P2860
Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Antibody persistence ten years ...... d third doses in older adults.
@ast
Antibody persistence ten years ...... d third doses in older adults.
@en
Antibody persistence ten years ...... d third doses in older adults.
@nl
type
label
Antibody persistence ten years ...... d third doses in older adults.
@ast
Antibody persistence ten years ...... d third doses in older adults.
@en
Antibody persistence ten years ...... d third doses in older adults.
@nl
prefLabel
Antibody persistence ten years ...... d third doses in older adults.
@ast
Antibody persistence ten years ...... d third doses in older adults.
@en
Antibody persistence ten years ...... d third doses in older adults.
@nl
P2093
P356
P1433
P1476
Antibody persistence ten years ...... d third doses in older adults.
@en
P2093
Adriana M Rueda
Charles L Liss
Daniel M Musher
Jennifer Raab
Monica L Walker
Patricia A Hoover
Richard D McFetridge
Rocio D Marchese
Susan B Manoff
P304
P356
10.4161/HV.7.9.15996
P577
2011-09-01T00:00:00Z